Breaking News From Pharma & Bio Ingredients
Biovail Rolls Out Glumetza in Canada
Posted on 2005-11-29 12:17:00
Biovail announced today that it has officially rolled out Glumetza in Canada. Developed in partnership with Depomed, Inc. of Menlo Park, California, Glumetza is the first once-daily, extended-release formulation of metformin on the Canadian market. Glumetza is being launched by Biovail Pharmaceuticals Canada (BPC), the Canadian sales and marketing division of Biovail Corporation. This launch further validates BPC's position as the number-one independent pharmaceutical commercial organization in the country.
"Hyperglycemia is a major cause of many of the complications for people who have diabetes, so keeping your blood sugar as close to normal as possible not only helps you to feel better, but will help to reduce the risk of long-term complications," said Doug Herman, Vice-President and General Manager of BPC. "Metformin is the most prescribed oral medication for the treatment of Type II diabetes. Providing Canadians with a once-daily metformin option to treat Type II diabetes is a great step toward enhanced patient adherence - and as a result, a great step forward toward helping to manage this disease."
Clinical data exists to show that reducing the frequency of daily dosing of oral diabetes medication can cause an improvement in patient compliance and metabolic control. Poor patient compliance to medications and dosing regimens represent a significant challenge to physicians in treating chronic disease - especially diabetes, due to the high number of medications that patients often have to take to control their disease. Glumetza offers a significant advantage to both physicians and patients by simplifying the dosage regimen of twice-a-day or three-times-a-day metformin to once a day.
Subscribe via RSS
